Modelos empíricos para estimar o acúmulo de matéria seca de capim-marandu com variáveis agrometeorológicas

O objetivo deste estudo foi testar modelos empíricos de regressão linear, para a predição do acúmulo de matéria seca (TAMS) de Urochloa brizantha cv. Marandu, em função de variáveis agrometeorológicas. Para gerar os modelos, foi utilizada a taxa média de acúmulo de matéria seca, em condições de sequeiro, entre 1998 e 2002. As variáveis avaliadas foram: temperaturas mínima, máxima e média, radiação global (Rg), graus-dia, evapotranspiração real (ETR) e potencial (ETP) obtidas a partir do balanço hídrico, unidades fototérmicas (UF) e índice climático de crescimento (ICC). As regressões univariada e multivariada mostraram boa capacidade de predição, com exceção para as que utilizam a UF. Os melhores resultados foram para a regressão multivariada, com Tmín, Rg e ETR: R², 0,84; raiz do quadrado médio do resíduo (RQMR), 14,72; e critério de informação de Akaike (CIA), 222,5. Na regressão linear univariada, destacaram-se as variáveis: graus-dia corrigido (R², 0,75; RQMR,17,84; e CIA, 242,6), temperatura mínima corrigida (R², 0,75; RQMR, 17,82; CIA, 244,1), e ICC (R², 0,74; RQMR, 17,85; CIA, 236,9). A correção das variáveis agrometeorológicas pela relação entre evapotranspiração real e potencial (ETR/ETP), em geral, melhora a predição da TAMS pelos modelos.

Ganho de peso e produtividade animal em capim-marandu sob pastejo rotativo e adubação nitrogenada

O objetivo deste trabalho foi avaliar metas de manejo para capim-marandu (Urochloa brizantha cv. Marandu) submetido a pastejo rotativo e a doses de nitrogênio, de janeiro de 2009 a abril de 2010. Os tratamentos consistiram da combinação de duas frequências de pastejo (altura pré-pastejo de 25 e 35 cm) e de duas doses de fertilizante nitrogenado (50 e 200 kg ha-1 por ano) em delineamento de blocos ao acaso com arranjo fatorial 2x2 e quatro repetições. A altura de pós-pastejo estipulada foi de 15 cm. Maiores valores de ganho de peso médio por animal por dia (0,629 e 0,511 kg dia-1) e por hectare (886 e 674 kg ha-1), bem como de taxa de lotação (3,13 e 2,85 UA ha-1), foram observados nos pastos manejados com altura pré-pastejo de 25 cm. A aplicação de 200 kg ha-1 de N resultou em aumentos na percentagem de folhas na massa de forragem pós-pastejo, nas taxas de acúmulo de forragem, na taxa de lotação e no ganho de peso por área. A mais adequada estratégia de manejo corresponde à altura pré-pastejo de 25 cm, independentemente da dose de nitrogênio utilizada.

Incidence and outcome of progressive multifocal leukoencephalopathy over 20 years of the Swiss HIV Cohort Study.

BACKGROUND: We investigated the incidence and outcome of progressive multifocal leukoencephalopathy (PML) in human immunodeficiency virus (HIV)-infected individuals before and after the introduction of combination antiretroviral therapy (cART) in 1996. METHODS: From 1988 through 2007, 226 cases of PML were reported to the Swiss HIV Cohort Study. By chart review, we confirmed 186 cases and recorded all-cause and PML-attributable mortality. For the survival analysis, 25 patients with postmortem diagnosis and 2 without CD4+ T cell counts were excluded, leaving a total of 159 patients (89 before 1996 and 70 during 1996-2007). RESULTS: The incidence rate of PML decreased from 0.24 cases per 100 patient-years (PY; 95% confidence interval [CI], 0.20-0.29 cases per 100 PY) before 1996 to 0.06 cases per 100 PY (95% CI, 0.04-0.10 cases per 100 PY) from 1996 onward. Patients who received a diagnosis before 1996 had a higher frequency of prior acquired immunodeficiency syndrome-defining conditions (P = .007) but similar CD4+ T cell counts (60 vs. 71 cells/microL; P = .25), compared with patients who received a diagnosis during 1996 or thereafter. The median time to PML-attributable death was 71 days (interquartile range, 44-140 days), compared with 90 days (interquartile range, 54-313 days) for all-cause mortality. The PML-attributable 1-year mortality rate decreased from 82.3 cases per 100 PY (95% CI, 58.8-115.1 cases per 100 PY) during the pre-cART era to 37.6 cases per 100 PY (95% CI, 23.4.-60.5 cases per 100 PY) during the cART era. In multivariate models, cART was the only factor associated with lower PML-attributable mortality (hazard ratio, 0.18; 95% CI, 0.07-0.50; P < .001), whereas all-cause mortality was associated with baseline CD4+ T cell count (hazard ratio per increase of 100 cells/microL, 0.52; 95% CI, 0.32-0.85; P = .010) and cART use (hazard ratio, 0.37; 95% CI, 0.19-0.75; P = .006). CONCLUSIONS: cART reduced the incidence and PML-attributable 1-year mortality, regardless of baseline CD4+ T cell count, whereas overall mortality was dependent on cART use and baseline CD4+ T cell count.

Azacytidine for acute myeloid leukemia in elderly or frail patients: a phase II trial (SAKK 30/07).

Abstract This phase II trial treated elderly or frail patients with acute myeloid leukemia (AML) with single-agent subcutaneous azacytidine at 100 mg/m(2), on 5 of 28 days for up to six cycles. Treatment was stopped for lack of response, or continued to progression in responders. The primary endpoint was response within 6 months. A response rate ≥ 34% was considered a positive trial outcome. From September 2008 to April 2010, 45 patients from 10 centers (median age 74 [55-86] years) were accrued. Patients received four (1-21) cycles. Best response was complete response/complete response with incomplete recovery of neutrophils and/or platelets (CR/CRi) in eight (18%; 95% confidence interval [CI]: 8-32%.), 0 (0%) partial response (PR), seven (16%) hematologic improvement, 17 (38%) stable disease. Three non-responding patients stopped treatment after six cycles, 31 patients stopped early and 11 patients continued treatment for 8-21 cycles. Adverse events (grade ≥ III) were infections (n = 13), febrile neutropenia (n = 8), thrombocytopenia (n = 7), dyspnea (p = 6), bleeding (n = 5) and anemia (n = 4). Median overall survival was 6 months. Peripheral blood blast counts, grouped at 30%, had a borderline significant association with response (p = 0.07). This modified azacytidine schedule is feasible for elderly or frail patients with AML in an outpatient setting with moderate, mainly hematologic, toxicity and response in a proportion of patients, although the primary objective was not reached.

[Archives de la parole]. , [L'autre jour m'y promenant] : [chanson] / [Ferdinand Brunot], collecteur ; [Marguerite Audebert, 85 ans], chant. [La destinée, la rose au bois] : [chanson] / [Ferdinand Brunot], collecteur ; [Amélie Moutard, 71 ans, cultivatrice], chant. [Le galant ridicule] : [chanson] / [Ferdinand Brunot], collecteur ; [Ferdinand Brunot], collecteur

[Traditions. France. Berry]

Redressement et liquidations judiciaires des entreprises (loi n ° 85-98 du 25 janvier 1985), administrateurs judiciaires

Collection : Journal officiel de la République française ; brochure 1034

The Influence of Process Conditions on the Deresination Efficiency in Mechanical Pulp Washing

The aim of this thesis was to produce information for the estimation of the flow balance of wood resin in mechanical pulping and to demonstrate the possibilities for improving the efficiency of deresination in practice. It was observed that chemical changes in wood resin take place only during peroxide bleaching, a significant amount of water dispersed wood resin is retained in the pulp mat during dewatering and the amount of wood resin in the solid phase of the process filtrates is very small. On the basis of this information there exist three parameters related to behaviour of wood resin that determine the flow balance in the process: 1. The liberation of wood resin to the pulp water phase 2. Theretention of water dispersed wood resin in dewatering 3. The proportion of wood resin degraded in the peroxide bleaching The effect of different factors on these parameters was evaluated with the help of laboratory studies and a literature survey. Also, information related to the values of these parameters in existing processes was obtained in mill measurements. With the help of this information, it was possible to evaluate the deresination efficiency and the effect of different factors on this efficiency in a pulping plant that produced low-freeness mechanical pulp. This evaluation showed that the wood resin content of mechanical pulp can be significantly decreased if there exists, in the process, a peroxide bleaching and subsequent washing stage. In the case of an optimal process configuration, as high as a 85 percent deresination efficiency seems to be possible with a water usage level of 8 m3/o.d.t.

Maneig agroecològic en parcel·les agrícoles de petits camperols a la zona maya de Campeche (México)

Amb l’oportunitat de viure de primera mà algunes experiències productives de diferents comunitats de la zona maya de Campeche (Mèxic) i treballant amb aquestes en l’àmbit productiu, organitzatiu i social, se’m presenta l’ocasió de realitzar aquest treball. A nivell productiu es treballa en el maneig .ecològic de les parcel·les dels camperols i a nivell socio-econòmic, s’incideix en la millora de les capacitats organitzatives i de gestió de recursos compartits, així com en la cerca d’alternatives de comercialització. Aquest projecte, té un peu dins de la cooperació al desenvolupament rural, entesa com una eina per assolir nous reptes en el desenvolupament econòmic local de los Chenes (regió del municipi de Hopelchém, Campeche). Es prioritza el desenvolupament humà, la igualtat d’oportunitats i la participació voluntària dels beneficiaris del projecte, fent de les seves habilitats personals i socials l’eix motor del projecte per a assolir una millora de la realitat socioeconòmica en la que viuen.

Additive effects of HLA alleles and innate immune genes determine viral outcome in HCV infection.

BACKGROUND: Chronic HCV infection is a leading cause of liver-related morbidity globally. The innate and adaptive immune responses are thought to be important in determining viral outcomes. Polymorphisms associated with the IFNL3 (IL28B) gene are strongly associated with spontaneous clearance and treatment outcomes. OBJECTIVE: This study investigates the importance of HLA genes in the context of genetic variation associated with the innate immune genes IFNL3 and KIR2DS3. DESIGN: We assess the collective influence of HLA and innate immune genes on viral outcomes in an Irish cohort of women (n=319) who had been infected from a single source as well as a more heterogeneous cohort (Swiss Cohort, n=461). In the Irish cohort, a number of HLA alleles are associated with different outcomes, and the impact of IFNL3-linked polymorphisms is profound. RESULTS: Logistic regression was performed on data from the Irish cohort, and indicates that the HLA-A*03 (OR 0.36 (0.15 to 0.89), p=0.027) -B*27 (OR 0.12 (0.03 to 0.45), p=<0.001), -DRB1*01:01 (OR 0.2 (0.07 to 0.61), p=0.005), -DRB1*04:01 (OR 0.31 (0.12 to 0.85, p=0.02) and the CC IFNL3 rs12979860 genotypes (OR 0.1 (0.04 to 0.23), p<0.001) are significantly associated with viral clearance. Furthermore, DQB1*02:01 (OR 4.2 (2.04 to 8.66), p=0.008), KIR2DS3 (OR 4.36 (1.62 to 11.74), p=0.004) and the rs12979860 IFNL3 'T' allele are associated with chronic infection. This study finds no interactive effect between IFNL3 and these Class I and II alleles in relation to viral clearance. There is a clear additive effect, however. Data from the Swiss cohort also confirms independent and additive effects of HLA Class I, II and IFNL3 genes in their prediction of viral outcome. CONCLUSIONS: This data supports a critical role for the adaptive immune response in the control of HCV in concert with the innate immune response.

Avaliação de genótipos de bananeira na região do baixo São Francisco, Sergipe

Este trabalho teve como objetivo avaliar o desempenho de 20 genótipos de bananeira nas condições edafoclimáticas da região do Baixo São Francisco-SE. O experimento foi instalado em área experimental da Embrapa Tabuleiros Costeiros, no município de Propriá- SE. O delineamento foi em blocos ao acaso, com quatro repetições e três touceiras úteis por parcela. Foram avaliados caracteres de crescimento e produção no primeiro e segundo ciclos. Os híbridos PV42-53, PV42-68, PV42-85 e FHIA-02, devido ao bom desempenho com relação ao peso do cacho e peso médio do fruto, podem ser recomendados para cultivo no Baixo São Francisco. O híbrido FHIA-18 apresentou excelentes características agronômicas, sendo uma alternativa a cultivar Prata-Anã. Os híbridos Ambrósia e Bucaneiro podem ser indicados por apresentarem cachos grandes e sabor semelhante às bananas do subgrupo Cavendish. O híbrido YB42-07 tem potencial para ser lançado como cultivar em áreas de cultivo de banana Maçã.

Konserttiohjelma 1900-07-01 - Ohjelma

Helsinki 1900

Konserttiohjelma 1900-07-02 - Ohjelma

Helsinki 1900

Micropropagação das bananeiras 'Prata-Anã' e 'FHIA 01' a partir de explantes de plantas tratadas com paclobutrazol

Com o objetivo de avaliar o desenvolvimento in vitro de explantes das bananeiras 'Prata-Anã' e 'FHIA 01' provenientes de plantas tratadas com paclobutrazol (PBZ), conduziu-se este experimento no Laboratório de Cultura de Células e Tecidos Vegetais, Setor de Fruticultura, DFT/UFV. Utilizou-se esquema fatorial 2 x 5, correspondendo às duas cultivares ('Prata-Anã' e 'FHIA 01') e cinco doses de PBZ (0,0; 0,5; 1,0; 1,5 e 2,0 g i.a. planta-1), em delineamento experimental inteiramente ao acaso, com número variável de repetições. Avaliaram-se, na parte aérea: taxa de brotação, altura e diâmetro, número de folhas, massa fresca e seca e intensidade da cor verde; e no sistema radicular: porcentagem de enraizamento, número de raízes, comprimento da maior raiz, massa fresca e seca, e a relação massa da raiz:massa da parte aérea. Foi observado que a altura da parte aérea foi reduzida a partir de 1,13 g i.a. planta-1, em ambas as cultivares. O diâmetro não foi alterado com o aumento das doses, mas nos explantes da 'Prata Anã' os diâmetros foram maiores que 'FHIA 01'. Para o número de folhas, as massas fresca e seca não apresentaram diferenças entre as doses e entre as cultivares. A intensidade da cor verde aumentou linearmente com o aumento das doses, em ambas as cultivares. A partir de 1,07 g i.a. planta-1, a taxa de brotação da 'Prata-Anã' foi inibida, enquanto a da 'FHIA 01' foi estimulada a partir de 0,85 g i.a. planta-1. Houve interação significativa para a porcentagem de enraizamento, onde se observaram valores mais baixos para a cultivar 'Prata-Anã' (64,71%), em relação à 'FHIA 01' (95,83%), na maior dose. Não foi observado efeito das doses de PBZ sobre a porcentagem de enraizamento de explantes da 'Prata-Anã', enquanto para 'FHIA 01' houve aumento linear do enraizamento com o aumento das doses, sendo que o maior valor encontrado foi de 95,18%. As demais características aumentaram linearmente com o aumento das doses de PBZ, para ambas as cultivares.

Thrombin-receptor antagonist vorapaxar in acute coronary syndromes

Background: Vorapaxar is a new oral protease-activated-receptor 1 (PAR-1) antagonist that inhibits thrombin-induced platelet activation. Methods: In this multinational, double-blind, randomized trial, we compared vorapaxar with placebo in 12,944 patients who had acute coronary syndromes without ST-segment elevation. The primary end point was a composite of death from cardiovascular causes, myocardial infarction, stroke, recurrent ischemia with rehospitalization, or urgent coronary revascularization. RESULTS: Follow-up in the trial was terminated early after a safety review. After a median follow-up of 502 days (interquartile range, 349 to 667), the primary end point occurred in 1031 of 6473 patients receiving vorapaxar versus 1102 of 6471 patients receiving placebo (Kaplan-Meier 2-year rate, 18.5% vs. 19.9%; hazard ratio, 0.92; 95% confidence interval [CI], 0.85 to 1.01; P = 0.07). A composite of death from cardiovascular causes, myocardial infarction, or stroke occurred in 822 patients in the vorapaxar group versus 910 in the placebo group (14.7% and 16.4%, respectively; hazard ratio, 0.89; 95% CI, 0.81 to 0.98; P = 0.02). Rates of moderate and severe bleeding were 7.2% in the vorapaxar group and 5.2% in the placebo group (hazard ratio, 1.35; 95% CI, 1.16 to 1.58; P<0.001). Intracranial hemorrhage rates were 1.1% and 0.2%, respectively (hazard ratio, 3.39; 95% CI, 1.78 to 6.45; P<0.001). Rates of nonhemorrhagic adverse events were similar in the two groups. Conclusions: In patients with acute coronary syndromes, the addition of vorapaxar to standard therapy did not significantly reduce the primary composite end point but significantly increased the risk of major bleeding, including intracranial hemorrhage. (Funded by Merck; TRACER ClinicalTrials.gov number, NCT00527943.)